Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program
Author:
Open Access
- 29 June 2022
- journal article
- editorial
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (6) , 2090777
Abstract
Japan’s immunization program resumed proactively recommending the use of the human papillomavirus (HPV) vaccine nationwide in April 2022, after suspending this recommendation in June 2013. The promotion of catch-up vaccinations is an urgent issue to reduce the increase in cervical cancer and other cancers caused by low vaccination rates. In addition, the National Immunization Program still has issues to be considered, such as the adoption of the 9-valent vaccine, establishment of an appropriate number of vaccinations according to age, and routine immunization of males. There is a history of eliminating the use of the measles, mumps, and rubella vaccine and the mouse brain-derived, purified inactivated Japanese encephalitis vaccine, as well as suspending the HPV vaccine recommendation in Japan. These decisions have led to the current preventable infectious disease burden. In order to make the right policy decisions based on science-based assessments, it is necessary to establish a safety assessment platform to evaluate the causal relationship between vaccines and adverse events following immunization. Information technology, which has been promoted with the coronavirus disease 2019 vaccine in the current pandemic, may assist in providing more detailed vaccine safety evaluations for other vaccines.Keywords
Funding Information
- No funding
This publication has 11 references indexed in Scilit:
- Japan relaunches its HPV vaccination drive. For thousands of women, it may be too late2022
- Trends in cervical cancer incidence and mortality of young and middle adults in JapanCancer Science, 2022
- Changing trends in HPV vaccination in JapanHuman Vaccines & Immunotherapeutics, 2021
- Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling studyThe Lancet Public Health, 2020
- Nationwide Survey of Hearing Loss Caused by Mumps during 2015-2016 in JapanNippon Jibiinkoka Gakkai Kaiho, 2018
- Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015MMWR. Morbidity and Mortality Weekly Report, 2018
- Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenJAMA, 2016
- Trends of Media Coverage on Human Papillomavirus Vaccination in Japanese NewspapersClinical Infectious Diseases, 2016
- Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccineUirusu, 2005
- Adverse events associated with MMR vaccines in JapanPediatrics International, 1996